TICKERNERD
Menu
CNTBCNTBHealthcare · Biotechnology

CNTB Stock Forecast: Connect Biopharma Holdings Ltd. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$2.55
+0.39% on the day

The 8 Wall Street analysts covering Connect Biopharma Holdings Ltd. hold a median 12-month price target of $7 — +174.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 15 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$160.6M
Ticker Nerd rank
20 / 100
Median analyst target
$7.00
Analysts covering
8
Total return, dividends reinvested
1W
+15.6%
1M
+8.3%
YTD
−9.6%
1Y
+18.6%
From 52W high
−30.9%
From 52W low
+93.6%
$1.32
$3.69
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CNTB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Connect Biopharma Holdings Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
20 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
79
Size
71
Revisions
47
Issuance
40
Value
36
Growth
22
Momentum
15
Quality
8
Volatility
4

Accruals (79): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (4): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CNTB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CNTB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26CNTBHigh $10.00Median $7.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $4.00Median $7.00High $10.00

The green dot is the last close — the median target sits +174.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 July 2026OppenheimerInitiatesOutperform$8.00
9 July 2026OppenheimerInitiatesOutperform—
26 June 2026Piper SandlerInitiatesOverweight—
25 June 2026HC Wainwright & Co.ReiteratesBuy—
26 May 2026Canaccord GenuityInitiatesBuy—
21 May 2026Cantor FitzgeraldInitiatesOverweight—
1 Apr 2026BTIGReiteratesBuy—
31 Mar 2026BTIGReiteratesBuy—
1 Dec 2025Lake StreetInitiatesBuy—
13 Nov 2025BTIGReiteratesBuy—
31 Oct 2025BTIGInitiatesBuy—
13 Aug 2025HC Wainwright & Co.ReiteratesBuy—
12 June 2025HC Wainwright & Co.AssumesBuy$7.00
1 Apr 2025HC Wainwright & Co.ReiteratesBuy—
31 Mar 2025HC Wainwright & Co.ReiteratesBuy—
6 Sept 2024HC Wainwright & Co.ReiteratesBuy—
13 June 2024HC Wainwright & Co.ReiteratesBuy—
17 Apr 2024HC Wainwright & Co.MaintainsBuy—
4 Mar 2024HC Wainwright & Co.InitiatesBuy—
13 Sept 2023Cantor FitzgeraldReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CNTB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CNTB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

Connect Biopharma Holdings Ltd. (CNTB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.5×

Cheaper than 86% of US stocks

Price / sales
54.4×

Cheaper than 6% of US stocks

Price / book
3.8×

Cheaper than 29% of US stocks

EV / EBITDA
−1.9×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
5666.7%

Higher than 99% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−636.0%

Higher than 7% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−140.5%

Higher than 10% of US stocks

Return on assets
−69.7%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CNTB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CNTBConnect Biopharma Holdings Ltd.$160.6M
20
OKUROnKure Therapeutics, Inc.$161.1M
55
HUMAHumacyte, Inc.$163.1M
18
TNYATenaya Therapeutics, Inc.$157.6M
40
CNTNCanton Strategic Holdings, Inc.$155.8M
13
NKTXNkarta, Inc.$166.1M
40
ARMPArmata Pharmaceuticals, Inc.$167.0M
66

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Connect Biopharma Holdings Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CNTB news & analysis

Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 12 Aug 2026positive

Connect Biopharma reported financial results for the three and six months ended June 30, 2026, and provided a business update. The company completed enrollment in both Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD, expects to report topline results in September 2026, and stated its cash runway is expected to last at least one year from the release date.

Why it matters — The completion of enrollment in both Phase 2 studies brings CNTB closer to key topline data in September 2026, while the confirmed cash runway supports ongoing operations for at least another year.

FAQ

Frequently asked questions about CNTB stock

What is the CNTB stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Connect Biopharma Holdings Ltd. have a median 12-month price target of $7, with estimates ranging from $4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CNTB stock a buy right now?

Of the 8 analysts covering Connect Biopharma Holdings Ltd., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Connect Biopharma Holdings Ltd. 20 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CNTB?

As at 15 Aug 2026, Connect Biopharma Holdings Ltd. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (79 of 100).

Will CNTB stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +174.5% from the last close, and Ticker Nerd's factor model ranks Connect Biopharma Holdings Ltd. 20 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CNTB stock forecast for 2030?

No analyst covering Connect Biopharma Holdings Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CNTB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $10 over the next 12 months.

How has CNTB stock performed over the past year?

Connect Biopharma Holdings Ltd. returned +18.6% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Connect Biopharma Holdings Ltd. do?

Connect Biopharma Holdings Ltd. is a global clinical-stage biopharmaceutical company focused on developing innovative therapies for T cell-driven inflammatory diseases.

What is the latest news on CNTB?

The most recent item we track (GlobeNewsWire, 12 Aug 2026): "Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update". Connect Biopharma reported financial results for the three and six months ended June 30, 2026, and provided a business update. The company completed enrollment in both Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD, expects to report topline results in September 2026, and stated its cash runway is expected to last at least one year from the release date.

Company

About Connect Biopharma Holdings Ltd.

Connect Biopharma Holdings Ltd. is a global clinical-stage biopharmaceutical company focused on developing innovative therapies for T cell-driven inflammatory diseases. Headquartered in San Diego, California with operations in the United States and China, the company builds a pipeline of proprietary small molecules and antibodies using functional T cell assays to identify and validate therapeutic targets. Its lead product candidate, rademikibart, is an antibody targeting interleukin-4 receptor alpha currently in Phase 3 clinical development for atopic dermatitis and asthma. The company's second product candidate, icanbelimod, is an oral small molecule modulator of Sphingosine 1-Phosphate Receptor 1 in Phase 2 development for ulcerative colitis and Crohn's disease. Connect Biopharma aims to improve treatment outcomes for patients with chronic inflammatory conditions by leveraging advanced immunological research and targeted drug development strategies.

CEO Dr. Barry David Quart Pharm.D. · 64 employees · United States · https://www.connectbiopharm.com